AbbVie Inc. $ABBV Shares Sold by Orange Investment Advisors Inc.

Orange Investment Advisors Inc. lowered its position in AbbVie Inc. (NYSE:ABBV) by 5.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,265 shares of the company’s stock after selling 2,318 shares during the period. AbbVie makes up about 1.4% of Orange Investment Advisors Inc.’s investment portfolio, making the stock its 16th biggest position. Orange Investment Advisors Inc.’s holdings in AbbVie were worth $11,318,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ABBV. Corient Private Wealth LP purchased a new stake in AbbVie during the second quarter worth $559,736,000. Legal & General Group Plc acquired a new stake in AbbVie in the second quarter valued at $2,905,952,000. Jupiter Topco LLC acquired a new stake in AbbVie in the second quarter valued at $1,560,354,000. Diamant Asset Management Inc. grew its holdings in AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after purchasing an additional 3,654,351 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of AbbVie in the second quarter valued at $817,473,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on ABBV. Leerink Partners lifted their price target on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Argus increased their price objective on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Barclays increased their price objective on shares of AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday. Oppenheimer raised their target price on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Finally, HSBC lifted their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $279.86.

AbbVie Stock Performance

ABBV stock opened at $285.66 on Monday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The stock’s 50 day moving average price is $266.33 and its 200 day moving average price is $242.01. The firm has a market cap of $504.70 billion, a P/E ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.